Illumina Reports Financial Results for Second Quarter 2004
Wednesday July 14, 4:15 pm ET
Revenues Increase 140% Over Second Quarter 2003
SAN DIEGO--(BUSINESS WIRE)--July 14, 2004--Illumina, Inc. (NASDAQ:ILMN - News) announced today its financial results for the second quarter and six-month period ended June 27, 2004.
For the quarter ended June 27, 2004, the Company reported revenue of $11.5 million, a 140% increase compared to revenue of $4.8 million in the second quarter of 2003. Product revenue for the period was $9.0 million, a $6.3 million increase over the second quarter of 2003. Revenue for the six-month period ended June 27, 2004 was $22.3 million, a 148% increase compared to revenue of $9.0 million for the same six-month period in 2003. For the quarter ended June 27, 2004, the Company reported a net loss of $3.5 million, or $0.10 per share, compared to a net loss of $8.6 million, or $0.27 per share, in the second quarter of 2003. Net loss for the six-month period ended June 27, 2004 was $7.4 million, or $0.22 per share, compared to a net loss of $17.6 million, or $0.55 per share, for the same six-month period in 2003. Cash and investments at June 27, 2004, including restricted cash, totaled $66.2 million.
During the quarter, Illumina announced an agreement with and installed at the University of Southern California's (USC) Keck School of Medicine a production-scale SNP genotyping BeadLab capable of generating routinely over eight hundred thousand genotypes per day. The Company also shipped twelve benchtop BeadStation systems to core labs and individual researchers for moderate-throughput genomics applications. After the end of the quarter, Illumina announced an additional BeadLab agreement with the University of California, Los Angeles (UCLA).
In April, Illumina announced the development of a line of fixed-content genotyping products based on a revolutionary new assay and Sentrix® BeadChip configuration. This line of microarray solutions will allow large-scale interrogation of variation in the human genome at many levels of resolution, accelerating the ability of researchers to cost-effectively unlock the genetic basis of disease. And in May, the Company announced breakthrough pricing for two new BeadChips that will, for the first time ever, enable parallel, genome-wide expression analysis of multiple samples on a single microarray. The gene expression products are expected to be available in the third quarter.
Commenting on the second quarter's results, Jay Flatley, Illumina President and CEO stated, "This was the first full quarter of BeadStation system sales and we are pleased to have exceeded our shipment goals on this new product. We received orders from all major geographic regions demonstrating the effectiveness of our growing worldwide sales and support network. The majority of BeadStation shipments were the 500GX model providing customers the ability to study both gene expression and genotyping, and reflecting the flexibility of our BeadArray technology."
"Our continued ability to provide high-performance, cost-effective products to customers helped us achieve our twelfth consecutive quarter of sequential revenue increases," stated Tim Kish, Illumina's CFO. "With gross margins again above 70%, increasing market acceptance of our new BeadStation systems and the upcoming rollout of our two whole genome BeadChip products, we remain well positioned to reach breakeven early in 2005," added Kish.
-0-
Other Quarterly News and Highlights
-- Year to date, Illumina has sold three BeadLabs and 14
BeadStations against a 2004 fiscal year milestone of 20 system
sales.
-- Illumina raised approximately $30.7 before expenses with a
common stock offering completed in May.
-- Illumina has signed 11 genotyping service agreements through
the second quarter compared to a full-year milestone target of
20 such agreements.
-- Expanded geographical sales and service coverage with the
addition of distributors in South Korea and Spain.
-- Published research articles and citations continue to expand.
In the May issue of Genome Research, Illumina authored two
research articles and coauthored a third with GlaxoSmithKline.
-- The U.S. Patent and Trade Office awarded one new patent to
Illumina, bringing our total to 32 issued or allowed and 71
pending.
A significant portion of the Company's revenue is derived from large individual transactions such as the sale of production genotyping systems and large genotyping service contracts, including the Company's work on the International HapMap project. Because these transactions do not occur regularly and there is a long sales cycle for such transactions, revenues of these types may not occur on a frequent or consistent basis. In addition, the amount of the Company's total revenues is subject to fluctuations in demand from seasonality impacts, the timing and amount of government grant funding programs, the timing and size of research projects performed by customers and changes in overall spending levels in the life sciences industry. Given the difficulty in predicting the timing and magnitude of sales of its products, the Company may experience quarter-to-quarter fluctuations in revenue, resulting in the potential for a sequential decline in quarterly revenue.
Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology -- now used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will correlate genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. |
